{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:07Z","timestamp":1740108307636,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00228-022-03283-5","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T09:04:00Z","timestamp":1645002240000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design\u00a0\u2014\u00a0The BIND study"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-4959","authenticated-orcid":false,"given":"I.","family":"Prins - Can","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. R. F.","family":"van Berlo - van de Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zeeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. G.","family":"Vermeij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"van \u2019t Riet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Taxis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. G. A.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"3283_CR1","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME (2019) Chronic kidney disease diagnosis and management. JAMA 322:1294\u20131304","journal-title":"JAMA"},{"key":"3283_CR2","unstructured":"KDIGO (2012) Clinical practice guidelines for the evaluation and management of chronic kidney disease. Accessed at www.kdigo.org. Consulted on 1 March 2021."},{"key":"3283_CR3","unstructured":"Summary of Product Characteristics: Resonium A. Accessed at www.cbg-meb.nl. Consulted on 1 March 2021."},{"key":"3283_CR4","doi-asserted-by":"crossref","unstructured":"Hoge RHL, Arbouw MEL, Radstake DWS, van Berlo-van de Laar IRF (2015) Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report. J Clin Pharm Ther\u00a040:355\u20137","DOI":"10.1111\/jcpt.12265"},{"key":"3283_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0196-0644(05)81893-1","volume":"21","author":"DR B\u00e9langer","year":"1992","unstructured":"B\u00e9langer DR, Tierney MG, Dickinson G (1992) Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann Emerg Med 21:1312\u20131315","journal-title":"Ann Emerg Med"},{"key":"3283_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/0140-6736(93)91195-R","volume":"341","author":"M McLean","year":"1993","unstructured":"McLean M, Kirkwood I, Epstein M, Jones B, Hall C (1993) Cation-exchange resin and inhibition of intestinal absorption of thyroxine. Lancet 341:1286","journal-title":"Lancet"},{"key":"3283_CR7","unstructured":"FDA Drug Safety Communication: FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs. Accessed at www.fda.gov. Consulted on 25 March 2021"},{"key":"3283_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","volume":"37","author":"J Sommer","year":"2020","unstructured":"Sommer J, Seeling A, Rupprecht H (2020) Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs Aging 37:359\u2013372","journal-title":"Drugs Aging"},{"key":"3283_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ckj\/sfz046","volume":"12","author":"IM Schmidt","year":"2019","unstructured":"Schmidt IM, Hubner S, Nadal J, Titze S, Schmid M, Barthlein B et al (2019) Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin Kidney J 12:663\u2013672","journal-title":"Clin Kidney J"},{"key":"3283_CR10","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1111\/bcp.13738","volume":"84","author":"SM Laville","year":"2018","unstructured":"Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D et al (2018) Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol 84:2811\u20132823","journal-title":"Br J Clin Pharmacol"},{"key":"3283_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12882-016-0317-4","volume":"17","author":"R Al-Ramahi","year":"2016","unstructured":"Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-Ghazaleh D, Yasin E et al (2016) Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephrol 17:96\u2013101","journal-title":"BMC Nephrol"},{"key":"3283_CR12","first-page":"125","volume":"9","author":"OJ Fasipe","year":"2017","unstructured":"Fasipe OJ, Akhideno PE, Nwaiwu O, Adelosoye AA (2017) Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the Nephrology Clinic of Lagos University Teaching Hospital in Sub-Saharan West Africa. Clinical Pharmacology: Advances and Applications 9:125\u2013132","journal-title":"Clinical Pharmacology: Advances and Applications"},{"key":"3283_CR13","doi-asserted-by":"crossref","unstructured":"Marquito AB, Da Silva Fernandes NM, Colugnati FAB, Baumgratz de Paula R (2014) Identifying potential drug interactions in chronic kidney disease patients. J Brass Nefrol\u00a036(1):26\u201334","DOI":"10.5935\/0101-2800.20140006"},{"key":"3283_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/pharmaceutics12080713","volume":"12","author":"G Santos-Diaz","year":"2020","unstructured":"Santos-Diaz G, Perez-Pico AM, Suarez-Santisteban MA, Garcia-Bernalt V, Mayordomo R, Dorado P (2020) Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceutics 12:713\u2013724","journal-title":"Pharmaceutics"},{"key":"3283_CR15","doi-asserted-by":"crossref","unstructured":"van Berlo\u2013van de Laar IR, Prins\u2013Can I, Schuiling-Veninga CC, Taxis K, Jansman FG (2021)\u00a0 Exploring co-dispensed drug use in patients on sevelamer or polystyrene sulfonate to identify potential novel binding interactions: a cross sectional in silico study : Potential novel binding interactions with resins. Int J Clin Pharm","DOI":"10.1007\/s11096-021-01355-7"},{"key":"3283_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.ajkd.2016.08.039","volume":"69","author":"HM Koncicki","year":"2016","unstructured":"Koncicki HM, Unruh M, Schell JO (2016) Pain management in CKD: a guide for nephrology providers. Am J Kidney Dis 69:451\u2013460","journal-title":"Am J Kidney Dis"},{"key":"3283_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2215\/CJN.05180418","volume":"14","author":"SN Davison","year":"2019","unstructured":"Davison SN (2019) Clinical pharmacology considerations in pain management in patients with advanced kidney failure. CJASN 14:917\u2013931","journal-title":"CJASN"},{"key":"3283_CR18","doi-asserted-by":"crossref","unstructured":"van Berlo\u2010van de Laar IR, Prins\u2010Can I, de Lange AA, Taxis K, Jansman FG (2021)\u00a0Binding interactions with sevelamer and polystyrene sulfonate in vitro.\u00a0Pharmacol Res Perspect 9:e00834","DOI":"10.1002\/prp2.834"},{"key":"3283_CR19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0091270009340783","volume":"49","author":"JR Walker","year":"2009","unstructured":"Walker JR, Brown K, Rohatagi S, Bathala MS, Xu C, Wickremasingha PK, Salazar DE, Mager DE (2009) Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, Colesevelam (Welchol). J Clin Pharmacol 49:1185\u20131195","journal-title":"J Clin Pharmacol"},{"key":"3283_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cpdd.307","volume":"6","author":"S Johansson","year":"2017","unstructured":"Johansson S, Leonsson-Zachrisson M, Knutson M, Specer AG, Labonte ED, Deshpande D et al (2017) Preclinical and healthy volunteer studies of potential drug-drug interactions between tenapanor and phosphate binders. Clin Pharmacol Drug Dev 6:448\u2013456","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3283_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1248\/bpb.19.1231","volume":"19","author":"A Nakai","year":"1996","unstructured":"Nakai A, Nishikata M, Matsuyama K, Ichikawa M (1996) Drug interaction between simvastatine and cholestyramine in vitro and in vivo. Biol Pharm Bull 19:1231\u20131233","journal-title":"Biol Pharm Bull"},{"key":"3283_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/AAC.19.2.326","volume":"19","author":"CY King","year":"1981","unstructured":"King CY, Barriere SL (1981) Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob Agents Chemother 19:326\u2013327","journal-title":"Antimicrob Agents Chemother"},{"key":"3283_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/00498250600839369","volume":"36","author":"S Muzeeb","year":"2006","unstructured":"Muzeeb S, Venkatesh P, Mullangi R, Srinivas NR (2006) Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite desemthylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica 36:838\u2013856","journal-title":"Xenobiotica"},{"key":"3283_CR24","first-page":"250","volume":"35","author":"W Muck","year":"1997","unstructured":"Muck W, Ritter W, Frey R, Wetzelsberger N, Lucker PW, Kuhlmann J (1997) Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35:250\u2013254","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3283_CR25","first-page":"50","volume":"204","author":"C Johansson","year":"1978","unstructured":"Johansson C, Adamsson U, Stiemer U, Lindsten T (1978) Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract. Acta Med Scan 204:50\u2013512","journal-title":"Acta Med Scan"},{"key":"3283_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2125.1998.00645.x","volume":"45","author":"MA Young","year":"1998","unstructured":"Young MA, Lettis S, Eastmond R (1998) Concomitant administration of cholestyramine influences the absorption of trioglitazone. Br J Clin Pharmacol 45:37\u201340","journal-title":"Br J Clin Pharmacol"},{"key":"3283_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0033-3182(88)72405-6","volume":"29","author":"DS Geeze","year":"1988","unstructured":"Geeze DS, Wise MG, Stigelman WH (1988) Doxepin-cholestyramine interaction. Psychosomatics 29:233\u2013236","journal-title":"Psychosomatics"},{"key":"3283_CR28","first-page":"93","volume":"41","author":"S Burke","year":"2001","unstructured":"Burke S, Amin N, Incerti C, Plone M, Watson N (2001) Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 41:93\u2013198","journal-title":"J Clin Pharmacol"},{"key":"3283_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/00912700122009881","volume":"41","author":"SK Burke","year":"2001","unstructured":"Burke SK, Amin NS, Incerti C, Plone MA, Lee JW (2001) Sevelamer hydrochloride (Renagel\u00ae), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 41:199\u2013205","journal-title":"J Clin Pharmacol"},{"key":"3283_CR30","unstructured":"Summary of product characteristics: amitriptyline HCl. Accessed at www.cbg-meb.nl. Consulted on 1 March 2021"},{"key":"3283_CR31","unstructured":"Committee for medicinal products for human use (CHMP) (2011) Guideline on bioanalytical method validation. European medicines agency. 21 July 2011"},{"key":"3283_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1053\/ajkd.2000.19094","volume":"36","author":"B van Vlem","year":"2000","unstructured":"van Vlem B, Schoonjans R, Vanholder R, de Vos M, Vandamme W, van Laecke S et al (2000) Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis 36:962\u2013968","journal-title":"Am J Kidney Dis"},{"key":"3283_CR33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/00365520410004505","volume":"39","author":"H Strid","year":"2004","unstructured":"Strid H, Simr\u00e9n M, Stotzer PO, Abrahamsson H, Bj\u00f6rnsson ES (2004) Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 39:516\u2013520","journal-title":"Scand J Gastroenterol"},{"key":"3283_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.mcna.2004.11.007","volume":"89","author":"S Gabardi","year":"2005","unstructured":"Gabardi S, Abramson S (2005) Drug Dosing in Chronic Kidney Disease. Med Clin N Am 89:649\u2013687","journal-title":"Med Clin N Am"},{"key":"3283_CR35","unstructured":"Summary of product characteristics: sorbisterit (2021) Accessed at www.cbg-meb.nl. Consulted on 4 May 2021"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03283-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:07:47Z","timestamp":1649750867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3283"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03283-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee, the 1964 Helsinki Declaration, and its later amendments. The trial protocol was approved by the independent ethics committee of Isala (Zwolle, Netherlands).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}